International Biotechnology Trust plc (LSE:IBT) — Market Cap & Net Worth
Market Cap & Net Worth: International Biotechnology Trust plc (IBT)
International Biotechnology Trust plc (LSE:IBT) has a market capitalization of $4.08 Million (GBX33.50 Billion) as of August 7, 2026. Listed on the LSE stock exchange, this UK-based company holds position #28947 globally and #526 in its home market, demonstrating a -1.87% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying International Biotechnology Trust plc's stock price GBX1050.00 by its total outstanding shares 31902834 (31.90 Million). See reinvestment intensity of International Biotechnology Trust plc to understand how much of operating cash flow is reinvested back into capital assets.
International Biotechnology Trust plc Market Cap History: 2015 to 2026
International Biotechnology Trust plc's market capitalization history from 2015 to 2026. Data shows growth from $1.51 Million to $4.08 Million (10.76% CAGR).
Index Memberships
International Biotechnology Trust plc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE All-Share
FTAS
|
$72.47 Billion | 0.01% | #376 of 573 |
Weight: International Biotechnology Trust plc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
International Biotechnology Trust plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how International Biotechnology Trust plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.20x
International Biotechnology Trust plc's market cap is 0.20 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.54 Million | $-6.06 Million | -$7.21 Million | -0.25x | N/A |
| 2017 | $1.82 Million | $46.35 Million | $45.25 Million | 0.04x | 0.04x |
| 2018 | $1.77 Million | $21.10 Million | $19.96 Million | 0.08x | 0.09x |
| 2019 | $2.02 Million | $-16.58 Million | -$17.54 Million | -0.12x | N/A |
| 2020 | $2.73 Million | $54.65 Million | $53.42 Million | 0.05x | 0.05x |
| 2021 | $2.61 Million | $29.12 Million | $27.89 Million | 0.09x | 0.09x |
| 2022 | $2.57 Million | $-21.10 Million | -$22.47 Million | -0.12x | N/A |
| 2023 | $2.44 Million | $8.49 Million | $6.81 Million | 0.29x | 0.36x |
| 2024 | $2.65 Million | $42.34 Million | $38.88 Million | 0.06x | 0.07x |
| 2025 | $3.74 Million | $18.69 Million | -$1.17 Million | 0.20x | N/A |
Competitor Companies of IBT by Market Capitalization
Companies near International Biotechnology Trust plc in the global market cap rankings as of August 7, 2026.
Key companies related to International Biotechnology Trust plc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #426 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #546 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #570 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $484.83 |
| #426 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $768.58 |
| #546 | Argen-X | BR:ARGX | $49.55 Billion | €748.60 |
| #570 | UCB SA | BR:UCB | $47.34 Billion | €229.20 |
International Biotechnology Trust plc Historical Marketcap From 2015 to 2026
Between 2015 and today, International Biotechnology Trust plc's market cap moved from $1.51 Million to $ 4.08 Million, with a yearly change of 10.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX4.08 Million | +8.92% |
| 2025 | GBX3.74 Million | +41.35% |
| 2024 | GBX2.65 Million | +8.47% |
| 2023 | GBX2.44 Million | -4.92% |
| 2022 | GBX2.57 Million | -1.47% |
| 2021 | GBX2.61 Million | -4.74% |
| 2020 | GBX2.73 Million | +35.65% |
| 2019 | GBX2.02 Million | +13.73% |
| 2018 | GBX1.77 Million | -2.59% |
| 2017 | GBX1.82 Million | +18.29% |
| 2016 | GBX1.54 Million | +1.62% |
| 2015 | GBX1.51 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 6th, 2026 the market cap of International Biotechnology Trust plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.08 Million USD |
| MoneyControl | $4.08 Million USD |
| MarketWatch | $4.08 Million USD |
| marketcap.company | $4.08 Million USD |
| Reuters | $4.08 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About International Biotechnology Trust plc
International Biotechnology Trust plc specializes in investments in development stage and late stage companies. The majority of the fund's assets are generally invested in smaller and mid-capitalization quoted companies, with a minority in larger capitalization quoted companies. It makes long only investments. It prefers to invest in quoted or unquoted biotechnology and life sciences companies fo… Read more